There have been several attempts to improve treatment and outcome of patients with primary mediastinal B-cell lymphoma (PMBL) and Burkitt's lymphoma (BL). In recent years, chemotherapy dose intensification and the addition of rituximab have led to a remarkable progress and have developed into integral parts of treatment for both entities of lymphoma [1][2][3][4]. Here, we report our monocenter results of a highdose methotrexate based alternating regimen with rituximab (B-ALL/ NHL 2002 protocol) in 15 patients with PMBL and 28 patients with sporadic BL. Since the early 1980s, protocols of GMALL have been continuously adapted and in the meantime they have become reference treatment for BL and B-ALL in Germany. The latest changes comprised the additional use of rituximab, standardized G-CSF support, implementation of high-dose cytarabine, intrathecal triple therapy, and age-adjusted stratification. Furthermore, we additionally amended supportive care with palifermin as it reduced severity and prevalence of mucositis [5].Almost all patients responded to chemotherapy, leading to an overall response rate of 98% (PMBL 100%, 95% confidence interval (CI) 1.0-1.0; BL 96.4%, 95%CI 0.68-1.0). Complete remission (CR) was achieved in 83.8% (PMBL 80%, BL 85.7%), and the rate of partial remission (PR) was 14% (20% PMBL, BL 10.7%). On average, the individual best response to chemotherapy was achieved after 3.68 courses.After initial response, three patients (two BL, one PMBL) experienced a progression or relapse within 3, 5, and 10 months, respectively. Thus, 5-year progression-free survival (PFS) was 93.3% (95%CI 0.74-1.0) for patients with PMBL and 82.1% (95%CI 0.67-0.96) for BL. Five-year overall survival (OS) was 100% for PMBL and 94.1% (95%CI 0.83-1.0) for BL in the younger group, and 100% and 63.6% (95%CI 0.35-0.92), respectively, in patients >55 years (Fig. 1a,b). Regarding the BL group, two patients died from treatment-related sepsis, a 74-year-old woman discontinued therapy, and two progressed during salvage therapy.Postchemotherapy consolidation radiotherapy was performed in 66.7% in PMBL and in 10.7% in BL. A total of 93% of patients with PMBL and 100% of patients with BL received prophylactic intrathecal therapy.Overall response and survival rate of 100% of all patients in the PMBL subgroup was observed. Fietz et al. [6] already reported a CR rate of 73% and an OS of 80% at 8.6 years in a cohort of 15 patients with PMBL treated according a prior B-ALL protocol of the GMALL (without rituximab). Improved OS in our cohort may be explained by recent changes such as the additional use of rituximab or high-dose cytarabine. Additional use of rituximab had predominantly shown benefit in nonmethotrexate but not in methotrexate-containing regimens [3,4,[7][8][9]. Preliminary results of a current protocol by Hoelzer et al. [10] with 42 patients with PMBL showed an inferior CR rate of 69%, but a comparable 3-year OS of 90% in patients younger than 55 years and of 67% in the elderly group (>55 years). However, this difference c...